Evidence map›Paper›PMID 40747931›Full record

ArticleJournal of medicinal chemistry2025

Development of the First Small-Molecule Inhibitor Targeting Oncostatin M for Treatment of Breast Cancer.

Cody L Wolf, Andrea Feci, Joseph P Tuccinardi, Grace H Coughlin, Kelsey A Holdaway, Thaaer Muhammed, Clyde Pruett, Darren Lighter, Cooper McGrath, Terrell Engmann and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Cody L WolfDepartment of Biomolecular Sciences, Boise State University, Boise, Idaho 83725, United States.ORCID 0000-0002-4769-9571
Andrea FeciDepartment of Chemistry and Biochemistry, Boise State University, Boise, Idaho 83725, United States.
Joseph P TuccinardiDepartment of Chemistry and Biochemistry, Boise State University, Boise, Idaho 83725, United States.ORCID 0000-0003-0630-4075
Grace H CoughlinDepartment of Chemistry and Biochemistry, Boise State University, Boise, Idaho 83725, United States.ORCID 0009-0009-7174-7068
Kelsey A HoldawayDepartment of Chemistry and Biochemistry, Boise State University, Boise, Idaho 83725, United States.
Thaaer MuhammedDepartment of Chemistry and Biochemistry, Boise State University, Boise, Idaho 83725, United States.
Clyde PruettDepartment of Biological Sciences, Boise State University, Boise, Idaho 83725, United States.
Darren LighterDepartment of Biological Sciences, Boise State University, Boise, Idaho 83725, United States.
Cooper McGrathDepartment of Biological Sciences, Boise State University, Boise, Idaho 83725, United States.
Terrell EngmannDepartment of Biomolecular Sciences, Boise State University, Boise, Idaho 83725, United States.
Maria Pou-TorresDepartment of Biomolecular Sciences, Boise State University, Boise, Idaho 83725, United States.
Brittany RushingDepartment of Chemistry and Biochemistry, Boise State University, Boise, Idaho 83725, United States.
Luke WoodburyBiomedical Research Institute, Boise State University, Boise, Idaho 83725, United States.
Sierra E HaileDepartment of Biological Sciences, Boise State University, Boise, Idaho 83725, United States.ORCID 0009-0000-4649-7006
Hannah ScottDepartment of Biological Sciences, Boise State University, Boise, Idaho 83725, United States.
Ken TawaraDepartment of Biomolecular Sciences, Boise State University, Boise, Idaho 83725, United States.
Simion DincaDepartment of Biomolecular Sciences, Boise State University, Boise, Idaho 83725, United States.
Dong XuBiomedical and Pharmaceutical Sciences, Idaho State University, Meridian, Idaho 83642, United States.ORCID 0000-0001-7056-2728
Matthew D KingDepartment of Chemistry and Biochemistry, Boise State University, Boise, Idaho 83725, United States.ORCID 0000-0003-1011-3108
Lisa Rose WarnerDepartment of Chemistry and Biochemistry, Boise State University, Boise, Idaho 83725, United States.
Cheryl L JorcykDepartment of Biological Sciences, Boise State University, Boise, Idaho 83725, United States.
Don L WarnerDepartment of Chemistry and Biochemistry, Boise State University, Boise, Idaho 83725, United States.ORCID 0009-0006-6033-8582

Funding

Women's health: interplay of maternal diet and key demographics on neurological health in the rural frontier and remote WestP20GM103408 · NIGMS · UNIVERSITY OF IDAHO · PI Carolyn Hovde Bohach · 2012 to 2026
$59.8M
VPS35 D620N inhibits autophagy through disrupted hyaluronic acid-CD44 signalingP20GM109095 · NIGMS · BOISE STATE UNIVERSITY · PI OXFORD, JULIA THOM · 2014 to 2023
$22.7M
PAR04-122, Extramural Research Facilities Construction:*C06RR020533 · NCRR · BOISE STATE UNIVERSITY · PI RUDIN, MARK JOSEPH · 2010 to 2010
$4.0M
The Southwest Idaho Bridges to the BaccalaureateR25GM123927 · NIGMS · BOISE STATE UNIVERSITY · PI JORCYK, CHERYL LYNN, LYSNE, STEVEN · 2017 to 2021
$1.6M
Southwest Idaho Bridges to Baccalaureate ProgramT34GM146634 · NIGMS · BOISE STATE UNIVERSITY · PI CHERYL LYNN JORCYK, Holly K Paquette · 2022 to 2026
$918k
OSM-induced IL-6 and ER status in metastatic breast cancerR15CA242471 · NCI · BOISE STATE UNIVERSITY · PI JORCYK, CHERYL LYNN · 2020 to 2020
$407k
Small Molecule Inhibitors of the Inflammatory Cytokine Oncostatin MR15CA271157 · NCI · BOISE STATE UNIVERSITY · PI WARNER, DON L · 2022 to 2022
$395k
NCI NIH HHS R15 CA242471NCI NIH HHS R15 CA271157NCRR NIH HHS C06 RR020533NIGMS NIH HHS P20 GM103408NIGMS NIH HHS P20 GM109095NIGMS NIH HHS R25 GM123927NIGMS NIH HHS T34 GM146634
6 · The paper itself

Abstract

Oncostatin M (OSM) is a proinflammatory cytokine implicated in inflammatory diseases and multiple cancers, especially breast cancer. To date, no federally approved anti-OSM therapeutics exist. We computationally screened ∼1.65 million compounds to identify small-molecule inhibitors (SMIs) of the OSM, and candidates were validated in human breast cancer models. We identified a tetrasubstituted furan (

Indexed as

Antineoplastic AgentsBreast NeoplasmsFuransOncostatin MSmall Molecule LibrariesAnimalsCell Line, TumorCell ProliferationFemaleHumansMiceSTAT3 Transcription FactorStructure-Activity RelationshipXenograft Model Antitumor AssaysAntineoplastic AgentsFuransOncostatin MSmall Molecule LibrariesSTAT3 Transcription Factor

Identifiers

PMID40747931
PMCPMC12362618

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.